Novel Estrogen Receptor Compounds Targeting ER-Positive Breast Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for effective treatments for breast cancer, particularly for estrogen receptor-positive breast cancer that are not addressed by existing therapies such as hormonal therapy, chemotherapy, and CDK inhibitors.
Innovation Solution
Development of novel compounds represented by formulas I, I-A, I-B, and I-C, which can be administered in pharmaceutical compositions to target and inhibit estrogen receptors, potentially offering a new approach for treating breast cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing hormonal therapy, chemotherapy, or CDK inhibitors are used to treat breast cancer, then treatment options are available, but there is still an unmet need for effective treatments particularly for estrogen receptor-positive breast cancer
Solution Approach 1:
The patent segments the existing treatment landscape by developing a novel compound class that specifically targets estrogen receptor-positive breast cancer through a different mechanism of action than existing therapies. The compounds of formula I represent a distinct therapeutic segment that addresses the unmet need in ER+ breast cancer treatment
Solution Approach 2:
The patent changes the chemical parameter space by introducing novel compounds with specific structural features (formula I with various substituent options for R1-R7, X, Y, Z, and A) that enable selective targeting of estrogen receptors. This parameter change in molecular structure creates new therapeutic options with potentially improved efficacy and different side effect profiles compared to existing treatments
2Adaptability or versatility
If novel compounds of formula I are developed to target estrogen receptors, then new therapeutic options are provided, but the complexity of compound synthesis and characterization increases
Solution Approach 1:
The patent establishes a universal platform (compounds of formula I) that can be adapted to treat estrogen receptor-positive breast cancer through various substituent combinations. The core structure serves multiple functions: it provides the necessary estrogen receptor binding capability while allowing customization through different R groups to optimize potency, selectivity, and pharmacokinetic properties
Solution Approach 2:
The patent applies local quality by allowing specific substitution patterns at different positions of the core structure (R1-R7 at various positions on the aromatic rings and heterocyclic systems). This enables optimization of specific molecular properties (binding affinity, metabolic stability, solubility) at local positions while maintaining the overall pharmacophore integrity
Data Source
AI summary
The present invention relates to novel compounds or pharmaceutically acceptable salts thereof, useful for the treatment of cancer. The present disclosure also relates to pharmaceutical composition of the novel compound and method of treating benign or malignant disease of the breast or reproductive tract, prostate cancer, or endometrial cancer using the same.